Anti-factor Xa Monitoring and Activated Charcoal for a Pediatric Patient With Rivaroxaban Overdose

مرکز و کتابخانه مطالعات اسلامی به زبان های اروپایی

منو

" Anti-factor Xa Monitoring and Activated Charcoal for a Pediatric Patient With Rivaroxaban Overdose "
Carr, Brendan M.; Roy, David J.; Bangh, Stacey A.; Hellmich, Thomas R.; Walker, Laura E.

Document Type	:	AL
Record Number	:	927983
Doc. No	:	LA0bd0146t
Language of Document	:	English
Main Entry	:	Carr, Brendan M.; Roy, David J.; Bangh, Stacey A.; Hellmich, Thomas R.; Walker, Laura E.
Title & Author	:	Anti-factor Xa Monitoring and Activated Charcoal for a Pediatric Patient With Rivaroxaban Overdose [Article]\ Carr, Brendan M.; Roy, David J.; Bangh, Stacey A.; Hellmich, Thomas R.; Walker, Laura E.
Title of Periodical	:	Clinical Practice and Cases in Emergency Medicine
Volume/ Issue Number	:	2/3
Date	:	2018
Abstract	:	Rivaroxaban, an oral anticoagulant, directly inhibits factor Xa (FXa). A 35-month-old boy was brought to the emergency department 15 minutes after ingesting 200 mg of rivaroxaban (16 mg/kg). Activated charcoal (AC) was administered; the patient was observed with monitoring of plasma anti-FXa levels and discharged the following day after an uneventful hospital observation. We identified two case series and seven case reports of potentially toxic rivaroxaban ingestion in the literature. No serious adverse effects were reported. The present case is the first reported use of anti-FXa monitoring after rivaroxaban ingestion. The magnitude of the effect of AC administration in this patient is unclear.